 October 30, 2009
Octapharma research cooperation further elucidates mechanism of action of octagam.
[...more] |
October 29, 2009
Octapharma Group and Fresenius Kabi enter into an Exclusive License, Development and Supply Agreement for a HESylated recombinant protein.
[...more] |
October 2, 2009
Octapharma AG Announces Second Quarter 2009 Results and Mid Term Outlook of the Market.
[...more] |
September 9, 2009
The UK Blood Advisory Group(SaBTO) recommends Variant Creutzfeld Jacob Disease (vCJD) risk-reduction strategy for fresh frozen plasma (FFP) Octapharma develop OctaplasLG® to offer a solution.
[...more] |
August 31, 2009
Octapharma Targeting the Major Risk ofHemophilia Treatment – FVIII Antibodies
[...more] |
May 8, 2009
Press Release - Octapharma comments on the CADTH Report on cost-effectiveness of Octaplas®
[...more] |
April 29, 2009
Press release - Swine Influenza Virus (SIV) Outbreak and Implications in the Transfusion of the Biopharmaceutical Pooled and Virally Inactivated Plasma for Transfusion Octaplas®
[...more] |
April 22, 2009
Press release - The Board of the Octapharma Group appoints Mr. Flemming Nielsen and Mr. Dennis Curtin as Members of the Board
[...more] |
April 21, 2009
Press release - The French Health and Sports Minister grants the founder of the Octapharma Group, Mr. Wolfgang Marguerre, the French Legion of Honor during a visit to Octapharma' s facilities in Lingolsheim, France
[...more] |
March 30, 2009
Press release - Octapharma AG Announces First-Ever Research Grants Program, Demonstrating Commitment to Cutting-Edge Clinical Research
[...more] |
February 16, 2009
Press release - Octapharma Results 2008
[...more] |
February 11, 2009
Press release - Octapharma starts phase II clinical study in Alzheimer’s disease with octagam®10%
[...more] |
